Zealand Pharma A/S (ZLDPF)
USD 113.28
(0.0%)
USD 113.28
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 387.15 Million DKK | -46.52% |
| 2022 | 723.89 Million DKK | -36.49% |
| 2021 | 1.13 Billion DKK | 52.48% |
| 2020 | 747.52 Million DKK | 109.48% |
| 2019 | 356.84 Million DKK | 214.35% |
| 2018 | 113.51 Million DKK | -45.63% |
| 2017 | 208.77 Million DKK | -49.87% |
| 2016 | 416.43 Million DKK | 8.88% |
| 2015 | 382.45 Million DKK | 11.2% |
| 2014 | 343.92 Million DKK | 1017.67% |
| 2013 | 30.77 Million DKK | 2.68% |
| 2012 | 29.96 Million DKK | 6.71% |
| 2011 | 28.08 Million DKK | -35.35% |
| 2010 | 43.44 Million DKK | 68.67% |
| 2009 | 25.75 Million DKK | 55.06% |
| 2008 | 16.61 Million DKK | -20.92% |
| 2007 | 21 Million DKK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 759.5 Million DKK | 1.42% |
| 2024 Q1 | 748.84 Million DKK | 93.42% |
| 2023 FY | 387.15 Million DKK | -46.52% |
| 2023 Q3 | 358.7 Million DKK | 11.32% |
| 2023 Q2 | 322.24 Million DKK | -51.71% |
| 2023 Q1 | 667.26 Million DKK | -7.82% |
| 2023 Q4 | 387.15 Million DKK | 7.93% |
| 2022 Q1 | 1.12 Billion DKK | -1.07% |
| 2022 FY | 723.89 Million DKK | -36.49% |
| 2022 Q4 | 723.89 Million DKK | -0.18% |
| 2022 Q3 | 725.16 Million DKK | -3.52% |
| 2022 Q2 | 751.6 Million DKK | -33.35% |
| 2021 Q2 | 537.43 Million DKK | 5.99% |
| 2021 FY | 1.13 Billion DKK | 52.48% |
| 2021 Q4 | 1.13 Billion DKK | 139.99% |
| 2021 Q3 | 474.95 Million DKK | -11.63% |
| 2021 Q1 | 507.08 Million DKK | -32.17% |
| 2020 Q1 | 346.2 Million DKK | -2.98% |
| 2020 Q3 | 469.14 Million DKK | -0.57% |
| 2020 Q4 | 747.52 Million DKK | 59.34% |
| 2020 FY | 747.52 Million DKK | 109.48% |
| 2020 Q2 | 471.85 Million DKK | 36.29% |
| 2019 Q3 | 304.4 Million DKK | 15.91% |
| 2019 Q1 | 266.22 Million DKK | 134.53% |
| 2019 Q2 | 262.62 Million DKK | -1.35% |
| 2019 FY | 356.84 Million DKK | 214.35% |
| 2019 Q4 | 356.84 Million DKK | 17.23% |
| 2018 Q4 | 113.51 Million DKK | -59.79% |
| 2018 Q2 | 205.89 Million DKK | 12.24% |
| 2018 FY | 113.51 Million DKK | -45.63% |
| 2018 Q1 | 183.43 Million DKK | -12.14% |
| 2018 Q3 | 282.3 Million DKK | 37.11% |
| 2017 Q4 | 208.77 Million DKK | 10.08% |
| 2017 FY | 208.77 Million DKK | -49.87% |
| 2017 Q3 | 189.65 Million DKK | -4.96% |
| 2017 Q2 | 199.54 Million DKK | -9.92% |
| 2017 Q1 | 221.51 Million DKK | -46.81% |
| 2016 Q1 | 356.31 Million DKK | -6.84% |
| 2016 FY | 416.43 Million DKK | 8.88% |
| 2016 Q4 | 416.43 Million DKK | 18.28% |
| 2016 Q3 | 352.07 Million DKK | -4.83% |
| 2016 Q2 | 369.93 Million DKK | 3.82% |
| 2015 Q2 | 353.77 Million DKK | -1.74% |
| 2015 FY | 382.45 Million DKK | 11.2% |
| 2015 Q3 | 376.31 Million DKK | 6.37% |
| 2015 Q1 | 360.06 Million DKK | 4.69% |
| 2015 Q4 | 382.45 Million DKK | 1.63% |
| 2014 Q3 | 41.55 Million DKK | 23.15% |
| 2014 FY | 343.92 Million DKK | 1017.67% |
| 2014 Q4 | 343.92 Million DKK | 727.69% |
| 2014 Q2 | 33.74 Million DKK | -7.99% |
| 2014 Q1 | 36.67 Million DKK | 19.17% |
| 2013 FY | 30.77 Million DKK | 2.68% |
| 2013 Q1 | 28.4 Million DKK | -5.21% |
| 2013 Q4 | 30.77 Million DKK | 28.56% |
| 2013 Q3 | 23.93 Million DKK | -34.76% |
| 2013 Q2 | 36.68 Million DKK | 29.15% |
| 2012 Q3 | 27.42 Million DKK | 25.05% |
| 2012 Q1 | 40.76 Million DKK | 45.16% |
| 2012 Q4 | 29.96 Million DKK | 9.29% |
| 2012 Q2 | 21.92 Million DKK | -46.21% |
| 2012 FY | 29.96 Million DKK | 6.71% |
| 2011 FY | 28.08 Million DKK | -35.35% |
| 2011 Q3 | 37.87 Million DKK | -27.0% |
| 2011 Q1 | 39.49 Million DKK | -9.08% |
| 2011 Q2 | 51.87 Million DKK | 31.35% |
| 2011 Q4 | 28.08 Million DKK | -25.84% |
| 2010 Q4 | 43.44 Million DKK | 0.0% |
| 2010 FY | 43.44 Million DKK | 68.67% |
| 2009 FY | 25.75 Million DKK | 55.06% |
| 2008 FY | 16.61 Million DKK | -20.92% |
| 2007 FY | 21 Million DKK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -10014.671% |
| CSL Limited | 18.62 Billion USD | 97.921% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -626.3% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -3940.421% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -91736.667% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -434.219% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -556.037% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -9952.23% |
| Mesoblast Limited | 188.44 Million USD | -105.447% |
| Marizyme, Inc. | 26.67 Million USD | -1351.335% |
| Genus plc | 485 Million USD | 20.174% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -6526.375% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -15285.673% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -10088.263% |
| ContraFect Corporation | 32.53 Million USD | -1090.108% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -19440.324% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| IMV Inc. | 37.93 Million USD | -920.631% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -3187.04% |
| MultiCell Technologies, Inc. | 1617.67 USD | -23932716.953% |
| Accustem Sciences Inc. | 1.07 Million USD | -35772.87% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -400.089% |
| EV Biologics, Inc. | 2.11 Million USD | -18204.556% |
| Q BioMed Inc. | 8.13 Million USD | -4660.321% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -366.816% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -7423.346% |
| Biomind Labs Inc. | 1.49 Million USD | -25734.172% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -2003.707% |
| Skye Bioscience, Inc. | 14.07 Million USD | -2651.192% |
| SQZ Biotechnologies Company | 50.03 Million USD | -673.705% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -272361.381% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -3989.977% |
| Intellipharmaceutics International Inc. | 12 Million USD | -3123.928% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -192402.834% |
| Neon Bloom, Inc. | 1.22 Million USD | -31473.144% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | -58.622% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -19160.147% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -6638.01% |
| GB Sciences, Inc. | 5.41 Million USD | -7046.284% |
| Alpha Cognition Inc. | 7.16 Million USD | -5303.576% |
| argenx SE | 444.95 Million USD | 12.99% |
| HST Global, Inc. | 593.59 Thousand USD | -65122.13% |
| Halberd Corporation | 728.71 Thousand USD | -53028.023% |
| Enzolytics Inc. | 365.26 Million USD | -5.991% |
| Resverlogix Corp. | 67.39 Million USD | -474.447% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -46059.441% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -416.757% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -226.101% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -22487.748% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -4181.638% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -1464.51% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -26900.804% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -3152.547% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -10463.074% |
| AVAX Technologies, Inc. | 3.99 Million USD | -9594.009% |
| ONE Bio Corp. | 27.49 Million USD | -1308.047% |
| Zenith Capital Corp. | 27.56 Thousand USD | -1404209.188% |
| Genscript Biotech Corporation | 1.32 Billion USD | 70.8% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -162123.973% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -10267.495% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -56764.669% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -14177.48% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -30646.2% |
| Agentix Corp. | 2.51 Million USD | -15321.052% |
| Adynxx, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 3.5 Million USD | -10946.182% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -578354.78% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -670.241% |
| BioStem Technologies, Inc. | 15.9 Million USD | -2334.216% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -83212.854% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -1411171.097% |
| LadRx Corporation | 2.2 Million USD | -17493.687% |
| Cell Source, Inc. | 15.8 Million USD | -2349.301% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -866093.843% |
| Regen BioPharma, Inc. | 5.45 Million USD | -6993.83% |
| Regen BioPharma, Inc. | 5.45 Million USD | -6993.83% |
| NovAccess Global Inc. | 7.86 Million USD | -4825.165% |
| Affymax, Inc. | 8.87 Million USD | -4264.266% |
| Itoco Inc. | 1.65 Million USD | -23319.155% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -18771.154% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -6300.298% |
| CytoDyn Inc. | 127.89 Million USD | -202.715% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -926127.9% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -24616.527% |
| Qrons Inc. | 1.48 Million USD | -25905.953% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -3405.15% |
| SYBLEU INC | 681.41 Thousand USD | -56716.351% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -47768.06% |
| Rebus Holdings, Inc. | 5.24 Million USD | -7285.616% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -6244.805% |
| Mobile Lads Corp. | 1.31 Million USD | -29375.058% |
| International Stem Cell Corporation | 5.27 Million USD | -7236.631% |
| Bioxytran, Inc. | 3.24 Million USD | -11814.264% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -61764.563% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -8285.175% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -844.37% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -1638.846% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -19015.063% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -6967.433% |
| Neutra Corp. | 973.52 Thousand USD | -39668.101% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -1234.324% |
| PureTech Health plc | 125.58 Million USD | -208.285% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -10204.528% |
| IXICO plc | 1.9 Million USD | -20273.395% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -1785.888% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -274.699% |
| CSL Limited | 18.62 Billion USD | 97.921% |
| Cellectis S.A. | 249.36 Million USD | -55.253% |